I know it's premature to express my deep appreciation to Linda Powers and her brilliant leadership for guiding this trial into fruition as we are awaiting topline data announcement anytime now ("later in the month of September")
God forgives and blesses I said it now!
If it is not for the publication of the interim blinded data in Journal of Translational Medicine in 2018, and the subsequent updates, I have not been so assured and ease in continually adding shares to my already large position whenever share prices were weakened. And the fact is now I have been able to average up!
Nobody is and should be happy for having gone through those dark days when the company has had to go through repeated deteriorating dilutions as if there would have been no end of it.
We now know how extremely hard for Linda to lengthen the trial not by months but years while maintaining the integrity of the trial because it's important and vital to bring the effect of immuno-oncology (IO) agents such as DCVax-L into full strength in treating cancer patients, which requires years of following up.
In effect, most other small biotech companies with phase 3 trials for GBM have failed due to a variety of reasons. For one important reason, I think it's because their leaders' lack of steel will, long-term vision and vulnerabilities to the market force which has been always hostile to promising small biotech companies. It seems we are an exception, a pleasant exception because we have an exceptional leader; all other big pharms have also failed in their trials of various agents in treating GBM patients despite very resourceful because their treatments are either unsafe and/or ineffective. We are only one standing!
Thanks to Linda we have come a long way and only a few yards away from reaching our first milestone goal: prove both the safety and efficacy of DCVax-L for GBM patients.
Again God forgives and blesses!
